Burden of Skin Diseases in Thailand: Analysis of Prevalence and DALYs Using Real-world Healthcare Service Data

Parinya Chamnan (parinya.chamnan@cardiomet-res.org)
Cardiometabolic Research Group, Department of Social Medicine, Sunprasitthiprasong Regional Hospital

Nutchada Prasitpuriprecha
Department of Social Medicine, Sunprasitthiprasong Regional Hospital

Sumonman Santaweesuk
Department of Social Medicine, Sunprasitthiprasong Regional Hospital

Prasit Boonkert
Strategy and Policy Division, National Health Security Office Region 10, Ubonratchathani

Research Article

Keywords: DALYs, disability adjusted life years, disease burden, prevalence, skin disease

DOI: https://doi.org/10.21203/rs.3.rs-109401/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

There is little evidence to describe the burden of skin diseases in developing countries and its accuracy remained questionable. The objective of this study was to examine prevalence and disability adjusted life years (DALYs) of skin diseases in a Thai general population in Ubonratchathani.

Methods

Based on real-world healthcare service data (diagnoses, prevalence, and cause-specific mortality) retrieved from the National Health Security Office reimbursement database, we used a simplified prevalence-based approach adopted in the Global Burden of Diseases to compute disease burden, measured as DALYs, of skin diseases. DALYs was calculated as the sum of years lost due to disability and years of life lost due to skin diseases, with adoption of previously published averaged disability weights and a 95% uncertainty interval (UI) estimated using a Bayesian bootstrap technique (normal distribution assumed).

Results

From a total population of 1,503,945, 110,205 people were affected by skin disease in 2018 – an overall prevalence of 7%. The prevalence varied across sex, age group and geographic areas. The most common skin diseases treated in Ubonratchathani’s healthcare services were dermatitis, bacterial skin diseases and urticaria (Prevalence of 2.35% (95%UI, 2.33-2.38), 2.21% (2.19-2.24) and 0.89% (0.87-0.90) respectively). Overall DALYs of skin diseases in Ubonratchathani population was 26,125 (95%UI 24,783 – 27,467), and this was higher in men than women. (DALYs 13,717 (12,846 – 14,588) and 12,408 (11,417 – 13,399) for men and women respectively). The greatest contributors of DALYs were cellulitis, decubitus ulcer and contact dermatitis (11,680, 4,806 and 1,598 years respectively). This pattern of skin disease burden was similarly observed in both sexes.

Conclusions

Skin disease caused substantial disease burden in this Thai population, with cellulitis being the largest contributor. This could be used to inform policy decision, health system planning and resource allocation regarding skin diseases.

Background

Skin disease is an important public health problem worldwide. The disease affects people of all ages and genders from different ethnicities and countries, particularly in tropical regions.(1) Skin diseases are common and can be presented in all level of healthcare services partly due to their symptoms and signs being easily recognized. According to the 2010 Global Burden of Disease (GBD) report, three skin diseases were among the top 10 most prevalent diseases globally.(2) Albeit generally low mortality of skin diseases, many skin disorders are chronic conditions and may be associated with reduced quality of life(3) and substantial morbidity.(3, 4) In effect, skin diseases could lead to significant years lost due to disability (YLD) – They were among the leading causes of YLDs worldwide.(5)

According to GBD of Skin Diseases 2010, skin diseases contributed to substantial burden with YLD of more than 33.7 million years, the fourth among all diseases worldwide. Skin conditions collectively resulted in the disability adjusted life years (DALYs) of 36.9 million years, being the 18th leading cause of global disease burden. The GBD 2017 Report showed that skin and subcutaneous diseases caused 44.1 million years of DALYs. The GBD of Skin Diseases 2010 and GBD 2017 Reports described indices of disease burden in different global regions and both developed and developing countries.(2, 6) A number of previous studies examining temporal changes in disease burden suggested that the number of DALYs for skin
diseases was not improved or even increased, with varying burdens across types of skin diseases and sexes. This was similar for both developed and developing countries.(4)

However, methods and parameters used to inform computations of DALYs in the previous studies, although being consecutively updated and improved, were largely based on expert panels, epidemiological studies, specific analytical methods and disability weighting techniques, which may be somewhat problematic.(5, 7) This would particularly have considerable impact on DALYs estimates in developing countries, where the quality and completeness of data sources (prevalence, incidence, disability and cause-specific mortality) may be unsatisfactorily low. This merits further efforts to improve these country-specific data to obtain more accurate and reliable estimates of disease burden. This study aimed to examine the prevalence and DALYs of skin diseases in a Thai general population using real-world healthcare service data. This would help inform policy decision and planning to address skin and subcutaneous diseases in tropical and developing countries.

**Methods**

This study examined the burden of skin diseases in a Thai general population in Ubonratchathani using data from health services and reimbursement database. Ubonratchathani locates in the Northeastern region of Thailand and is the country's fourth largest province with a total population of 1,503,945 in 2018. Health service data have been standardized and stored in electronic health records in all levels of healthcare services, primary to tertiary care, for more than 15 years. Service data include personal and medical history, physical examination, investigations, diagnoses, medical treatments and procedures, follow-up, health promotion and disease prevention activities and vital status. All the service data are entered and stored in 43 separated folders, each of which is linked with unique national identification numbers. The data are then retrieved through a centralized database system called ‘Health Data Center’ and assembled and audited in a database of the National Health Security Office (NHSO) for reimbursement purpose.

After the approval from the Sunprasitthiprasong Hospital Ethics Committee (Ref no. 043/2557), demographic data, skin disease diagnoses and vital status for 1,503,945 residents of Ubonratchathani were anonymously retrieved from the NHSO database with assistance from the NHSO’s IT manager. Diagnostic data included whether an individual was diagnosed with skin diseases, diagnoses of skin diseases according to the 10th revision codes of the International Classification of Diseases (ICD-10 codes) and respective visit dates between 1st January 2018 and 31st December 2018. Vital status (dead/alive, causes and date of death) was obtained and cross-validated with national death certificates. In 2006, the Public Health Office of Ubonratchathani in collaboration with the University of Queensland started a project called ‘SPICE-COD’, using a verbal autopsy technique by local health care officers to improve the accuracy of causes of deaths data in Ubonratchathani. A validation study by Muangmai W, et al. suggested that the accuracy of data on causes of death significantly improved from 59% in 2007 to 71% in 2009, with a substantial reduction in the proportion of unknown cause of death.(8) This approach has been put in place since 2006 and it has helped assure accurate and reliable data on vital status and causes of death in Ubonratchathani’s population.

Sample size determination was based on research questions to examine the prevalence of different skin diseases according to the GBD 2017. Based on prevalence data reported in a study by Fasih S, et al.(9) with a 95% confidence and 10% margin of error allowed, a minimum of 63,641 participants would be needed for this study.(10) However, we decided to use data on all individuals residing in Ubonratchathani in 2018 as this would increase the study power and reduce biased selection at no additional expenses.

**Classification of skin diseases**

Based on the GBD 2017, 22 skin and subcutaneous diseases were selected and classified according to the ICD-10 codes obtained from the NHSO database (Supplementary Table 1). These included dermatitis (atopic dermatitis, seborrheic dermatitis, contact dermatitis), viral skin diseases (wart, molluscum contagiosum), fungal skin diseases (tinea capitis, other
fungal skin diseases), bacterial skin diseases (impetigo, pyoderma, cellulitis, abscess and other bacterial skin diseases), acne vulgaris, psoriasis, alopecia areata, scabies, melanoma, squamous cell carcinoma and basal cell carcinoma, carcinoma in situ, pruritus, urticaria, decubitus ulcer and other skin and subcutaneous diseases. According to current ICD coding systems, squamous cell carcinoma and basal cell carcinoma are not coded as separate diagnoses as the two malignancies are captured under a single diagnostic code of non-melanoma skin cancers.

**Estimation of prevalence of skin diseases and disease-specific mortality**

Based on the NHSO database, the overall and cause-specific prevalence of skin diseases was calculated as the number of individuals diagnosed with skin diseases divided by a total population of Ubonratchathani, with 95% uncertainty interval (UI) estimated using the Bayesian bootstrap technique (normal distribution assumed). The prevalence estimates were computed for the overall population and by sexes and districts. According to Karimkhani C. et al,(11) age- and sex-specific mortality was obtained for six skin and subcutaneous diseases: cellulitis, decubitus ulcer, abscess and other bacterial skin diseases, melanoma, squamous cell carcinoma, and other skin and subcutaneous diseases. This was based on mortality observed in individuals diagnosed with the above skin diseases in 2018.

**Estimation of DALYs attributable to skin diseases**

Using a simplified approach to calculation of DALYs (prevalence-based) adopted in the GBD 2010,(12) we computed DALYs as the sum of years lost due to disability (YLDs) and years of life lost (YLLs) due to skin diseases for each sex, age group, and type of skin diseases. The prevalence estimates were multiplied by averaged disability weights to calculate YLDs resulting from each type of skin disease. The averaged disability weights were derived from the GBD 2017.(13) Due to disease severity not being captured in electronic health records for most skin diseases, a single constant value of averaged disability weight was applied for each individual skin disease. YLLs were calculated as the sum of each death multiplied by the standard life expectancy at each age. As described earlier, deaths due to the selected skin diseases were identified through the NHSO database. The standard life expectancy for each sex and 5-year age group was taken from the Public Health Statistic A.D. 2018 Report convened by Thailand’s Ministry of Public Health (Strategy and Planning Division).(14) All analyses were performed using STATA 14.2 statistical package.

**Results**

**Prevalence of skin diseases**

Out of 1,503,945 people residing in Ubonratchathani, 110,205 were diagnosed with at least one of skin diseases, a prevalence of 7.33% (95% UI 7.29 – 7.37). Table 1 shows the number and prevalence of skin diseases diagnosed and treated in Ubonratchathani’s healthcare services in 2018. The prevalence of skin diseases varied substantially from lower than 0.01% to 2.35%. The highest prevalence was observed for dermatitis, bacterial skin infection and urticaria (2.35%, 2.21% and 0.89% respectively). Contact dermatitis constituted most cases of all dermatitis, with the prevalence of 0.98%. Considering skin malignancies, 435 cases of malignant melanoma were treated in Ubonratchathani’s healthcare services including a special cancer hospital, accounting for a prevalence of 0.03% or 30 per 100,000 population. There were 222 cases of non-melanoma skin cancers (squamous and basal cell carcinoma combined), a prevalence of 10 per 100,000 population.

Figure 1 shows the prevalence of skin diseases by district. There was great discrepancy in the prevalence of skin diseases across 25 districts of Ubonratchathani, ranging from 5.35% to 15.85%. The districts close to the border between Thailand and Lao PDR appeared to have lower skin disease prevalence than those located further from the border. The highest prevalence were observed in Muang Sam Sip, Nam Khun and Thung Si Udom Districts (15.85%, 10.53%, 9.30%...
respectively). The districts with the lowest skin disease prevalence were Khong Chiam, Khemmarat and Warin Chamrap Districts (5.35%, 5.51%, 5.57% respectively).

**YLLs, YLD and DALYs attributable to skin diseases**

Numbers of deaths and YLLs for six skin diseases overall and by sex are shown in Supplementary Table 2. Most deaths and YLLs were from cellulitis – 606 deaths contributing to 10,695 years of life lost, Decubitus ulcer and other skin and subcutaneous diseases contributed to 4,654 and 4,535 years of life lost. With a relatively small number of deaths from squamous/basal cell carcinoma and melanoma (35 and 24 deaths), 590 and 393 years of life were lost due to the two skin malignancies, while there were no deaths from abscess and other bacterial skin diseases. Males contributed to more YLLs than females similarly for all the diseases. Years lost due to disability from skin diseases in Ubonratchathani was as high as 5,259 (95%UI 5,206 – 5,312) years (Supplementary Table 3). The top 3 diseases that contributed most YLDs were contact dermatitis, urticaria and cellulitis (YLDs 1,598, 1,445 and 985 years). These together contributed to 65% of all YLDs. Melanoma resulted in a total YLD of 144 years. When using a disability weight of squamous cell carcinoma, non-melanoma skin cancers contributed to 48 YLDs. In a sensitivity analysis using a disability weight of basal cell carcinoma, the diseases caused only 2.4 YLDs. Of note, females had higher YLDs than males for all skin diseases, except for cellulitis, impetigo, psoriasis and decubitus ulcer.

Table 2 shows the estimated YLLs, YLDs and DALYs due to skin diseases in the population of Ubonratchathani, overall and by sex. The all-age all-cause DALYs in 2018 was 26,124.7 (95%UI 24,782.8 – 27,466.6). Overall, males had a slightly higher level of DALYs than females (DALYs 13,716.8 (12845.6 – 14,587.9) and 12,407.9 (11,416.7 – 13,399.1) respectively). The largest contribution of a single cause to DALYs in Ubonratchathani province was from cellulitis, which accounted for up to 45% of total DALYs. This was followed by decubitus ulcer and contact dermatitis, which together contributed to another 25% of the total DALYs. For certain skin diseases including cellulitis, decubitus ulcer and skin cancers, they contributed to more DALYs in males than females, while other diseases caused more DALYs in females than males. Figures 2 and 3 show DALYs due to different skin diseases in ascending order in males and females. Considering a single cause, cellulitis, decubitus ulcer and contact dermatitis similarly caused most DALYs in both males and females, with the top three diseases accounted for almost 70% of the total DALYs in each sex.

The number of DALYs due to melanoma was 537.1 (362.4 – 711.9), with a 1.4-time higher DALYs observed in males than females. Based on the scenario using disability weight of basal cell carcinoma, basal and squamous cell carcinomas caused 637.9 (438.5 – 837.3) of DALYs. In a sensitivity analysis using disability weight of squamous cell carcinoma, the two diseases caused only 2.4 (2.1 – 2.8) of DALYs.

**Discussion**

In the present study, we described the burden of skin and subcutaneous diseases in a Thai population in Ubonratchathani, using real-world healthcare service data. The overall prevalence of skin diseases was as high as 7% and varied across sex, age group and geographic areas. Dermatitis, bacterial skin infection and urticaria were the most common skin diseases. DALYs attributable to skin diseases was 26,125, and generally higher in males than females. Cellulitis, decubitus ulcer and contact dermatitis were the main causes of DALYs in this population.

Skin diseases were common worldwide, although the overall prevalence varied greatly across different countries. The overall prevalence of skin diseases in the present study was approximately 7%. This was considerably lower than the prevalence reported in other population-based survey studies, the overall prevalence of 15% and 27% reported in Bangladesh and European countries respectively.(16, 17) The discrepancy may be explained by that the Bangladesh study was conducted in one rural community without systemic sampling of participants and therefore prone to biased selection – those with symptoms and signs of skin diseases were likely participating, hence high prevalence. Additionally, a population-based survey in European countries described a lifetime prevalence, whereas our study reported the prevalence of any skin
diseases diagnosed and recorded in electronic health records in 2018. Differences in study settings, computation methods and definitions may make it difficult to compare skin disease prevalence across studies.

Comparison in skin disease prevalence is even more challenging when considering pattern or types of skin diseases. Based on the GBD of skin diseases 2010, fungal skin diseases, acne vulgaris and other skin and subcutaneous diseases were among the top 10 most prevalent diseases globally,(2) Dermatitis was one of the most prevalent skin diseases worldwide and the prevalence of dermatitis and its subtypes varied across populations. Dermatitis constituted 21-32% of all skin diseases.(9, 16, 18, 19) While atopic dermatitis represented most cases of dermatitis in developed countries,(6, 17, 20-22) contact dermatitis constituted most cases of dermatitis in our study and some European countries.(17) Skin infestation from scabies was prevalent in developing countries,(9, 16, 18) but rarely occurred in developed countries. For example, the prevalence of scabies was as high as 15% in Pakistan population,(9) while the figure was lower than 1% in this Thai population and most developed countries.(2) Interestingly, warts and acne topped the ranking of the most prevalent skin diseases in European countries,(17) while they were less prevalent in developing countries.(2) These differences may suggest true discrepancies in the pattern of skin diseases between countries and geographic regions or simply reflect different age groups of study participants and methods to obtain the prevalence estimates.

Skin diseases contribute to substantial disease burden and this reportedly varied by type of skin diseases and differed across global regions and countries. Consistent with the GBD 2017 and other previous population-specific studies, our study showed that dermatitis was among major causes of DALYs, albeit different burdens being caused by its different subtypes. For example, atopic dermatitis predominated the burden of all dermatitis in developed countries,(23) while contact dermatitis topped the list of dermatitis in our study. While cellulitis contributed to 45% of DALYs due to skin diseases in the present study, it resulted in only 1% of the total DALYs from skin diseases globally.(6) This discrepancy may reflect the contribution to DALYs of high prevalence of contact dermatitis and high premature mortality from cellulitis in a Thai population in relation to other populations. This relatively high burden of cellulitis and subcutaneous bacterial infection in Thailand might simply reflect lifestyle of people in the region where traditional farming remained predominant with disproportionately high use of agricultural chemicals. This may also suggest possible differences in healthcare service systems and quality of healthcare between countries. Besides, this may be explained by differences between these studies in the quality and completeness of data on diagnoses, related consequences and cause-specific mortality used to calculate DALYs.

Sex differences in DALYs due to skin diseases exist in many populations. This may be attributable to differences between sexes in the pattern of skin disease burden. Consistent to previous studies,(2, 6) our study found that YLLs constituted higher relative contribution to DALYs in men than women. Men may be more likely to be affected by fatal skin diseases such as skin cancers, cellulitis, and other serious skin infections, while women may be more likely to suffer from non-fatal disabling skin conditions such as dermatitis, pruritus and urticaria. Interestingly, while the GBD 2017 and GBD of Skin Diseases 2010 Reports suggested that woman had higher overall burden from skin and subcutaneous diseases than men, (2) our study showed opposite results. This might reflect true differences in the patterns of disease burden caused by skin disorders in the Thai population and other populations, or might be explained by a difference in data sources and methods to compute these indices of disease burden.

Skin cancers contribute to significant burden of skin diseases, albeit with disproportionate contributions of different skin cancers in different countries. While non-melanoma skin cancers (both basal and squamous cell carcinoma) were reportedly the most common skin malignancies in most Caucasian and Asian populations,(24-26) our study showed different results with malignant melanoma predominated in this Thai population. This could be due to differences between countries in climates and sun exposure and protection behaviors or that the Thais may have skin type that protects them from Ultraviolet B radiation than Caucasians and other Asians.(25) When considering DALYs, our study is consistent with many previous studies suggesting that malignant melanoma caused the higher disease burden than non-melanoma skin
cancers, compared to that of melanoma, and disproportionate rises in skin cancers incidence in light-skinned populations. (23, 27)

This study was among the first to examine prevalence and burden of skin diseases measured as DALYs in people of all ages in developing countries, using the real-world healthcare service and mortality data and standard computation techniques. However, our study had some limitations. First, diagnoses of skin and subcutaneous diseases based on respective ICD-10 codes from electronic health records did not contain data on disease severity. This could have altered the estimation of YLDs and hence DALYs in our study. However, this may at least represent the burden in real-world settings. Besides, the current ICD-10 coding system did not allow separate ICD codes for squamous and basal cell carcinomas. Applying the averaged disability weight of squamous cell carcinoma to the computation of YLDs and DALYs for patients with either squamous or basal cell carcinomas would lead to underestimation of these measures of disease burden. However, a sensitivity analysis using the averaged disability weight of basal cell carcinoma would reflect the possible upper-most estimates of the disease burden of both diseases. In addition, diagnoses of skin diseases were made by various health professions from primary care nurse and medical practitioners to tertiary care medical specialists and dermatologists. Therefore, there may be uncertainty about the accuracy and completeness of diagnostic information. However, all hospital diagnoses were routinely checked and coded by trained coder and then validated by the NHSO. Therefore, this method of cases ascertainment was likely to accurately capture diagnoses and burden of skin diseases in real-world clinical practices. A verification study to examine the accuracy of skin disease diagnoses may also be needed. Lastly, as our study was based on data from mixed urban-rural communities in Thailand, the generalizability of our findings to other populations and countries may be limited.

Conclusions

Skin disease caused considerable disease burden, measured as both prevalence and DALYs, in this Thai population and its contribution to the disease burden varied across sexes, age group and types of skin diseases. These estimates of disease burden will be useful in policy development and decision, health system planning and resource allocation with regards to skin diseases in Thailand and other developing countries.

Declarations

Ethics approval and consent to participate:

The present study was approved by the Ethics Committee of Sanpasitthiprasong Hospital (ref no. 043/2557). Need for participant's informed consent was waived off by the Ethics Committee of Sanpasitthiprasong Hospital as this study retrospectively used anonymous data from electronic health records and reimbursement data. All methods in this study were performed in compliance with the International Conference on Harmonization (ICH) and the principles of the Declaration of Helsinki.

Consent for publication:

Not applicable

Availability of data and materials:

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Competing interests:

The authors declare that they have no competing interests
**Funding:**

NP was partially supported by the research bursaries from the In-Service Family Medicine Residency Training (IS-FMERT) Program. The sponsor did not participate in the design or conduct of this study; in the collection, management, analysis, or interpretation of data; in the writing of the manuscript; or in the preparation, review, approval, or decision to submit this manuscript for publication. The views expressed in this publication are those of the authors and not necessarily those of the IS-FMERT Program, Sunprasitthiprasong Regional Hospital and the National Health Security Office.

**Authors’ contributions:**

PC had full access to all of the data in the study and takes responsibility for the accuracy of the data analysis and had final responsibility for the decision to submit for publication. As the corresponding author, PC has the right to grant on behalf of all authors and does grant on behalf of all authors. PC and NP were responsible for the study concept and design and drafting of the manuscript. PC was responsible for the acquisition of the data. PC, NP, SS and PB analysed and interpreted the data. All authors were responsible for critical revision of the manuscript for important intellectual content and approved the final version.

**Acknowledgements:**

We would like to thank Dr Denchai Tangmanokul, Head of the Department of Social Medicine, Sunprasitthiprasong Hospital for his general support for this study. We are grateful for the National Health Security Office Region 10 for support on service reimbursement data.

**References**

1. Nguyen SH, Nguyen LH, Vu GT, Nguyen CT, Le THT, Tran BX, et al. Health-Related quality of life impairment among patients with different skin diseases in Vietnam: a cross-sectional study. International journal of environmental research and public health. 2019;16(3):305.

2. Hay RJ, Johns NE, Williams HC, Bolliger IW, Dellavalle RP, Margolis DJ, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. Journal of Investigative Dermatology. 2014;134(6):1527-34.

3. Kalia S, Haiducu ML. The burden of skin disease in the United States and Canada. Dermatologic clinics. 2012;30(1):5-18.

4. Mounessa J, Braunberger T, Dunnick CA, Dellavalle RP. Minimal improvements in the global burden of skin disease from 1990 to 2013. Journal of the American Academy of Dermatology. 2017;76(1):148.

5. Seth D, Cheldize K, Brown D, Freeman EE. Global burden of skin disease: Inequities and innovations. Current dermatology reports. 2017;6(3):204-10.

6. Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1859-922.

7. Salomon JA. New disability weights for the global burden of disease. SciELO Public Health; 2010.

8. Mungmai W. Verbal Autopsy Model Development in Ubon Ratchathani 2007-2010. Journal of Health Science. 2018;19(5):687-94.

9. Fasih S, Arif AB, Younas S. Pattern of skin diseases in Abbas Institute of Medical Sciences, Muzaffarabad. Pakistan Journal of Physiology. 2017;13(4):26-9.

10. Campbell M. Biostatistics: A Foundation for Analysis in the Health Sciences, By Wayne W. Daniel. Citeseer; 1996.
11. Karimkhani C, Dellavalle RP, Karimi SM, Rahimi-Movaghar V, Pourmalek F, Ahmad Kiadaliri A, et al. Burden of skin and subcutaneous diseases in Iran and neighboring countries: Results from the global burden of disease study 2015. Archives of Iranian medicine. 2017;20(7):429-40.

12. Murray CJ, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C, et al. GBD 2010: design, definitions, and metrics. The Lancet. 2012;380(9859):2063-6.

13. Network GBoDC. Global Burden of Disease Study 2017 (GBD 2017) Disability Weights: Institute for Health Metrics and Evaluation (IHME); 2018 [updated 30/03/2019. Available from: http://ghdx.healthdata.org/record/ihme-data/gbd-2017-disability-weights.

14. Thailand TMoPh. Public Health Statistics A.D.2018 Nonthaburi: The Ministry of Public health Thailand; 2018 [21]. Available from: http://bps.moph.go.th/new_bps/sites/default/files/statistic%2061.pdf.

15. Efron B. Bayesian inference and the parametric bootstrap. The annals of applied statistics. 2012;6(4):1971.

16. Ahmed N, Islam M, Farjana S. Pattern of Skin Diseases: Experience from a Rural Community of Bangladesh. Bangladesh Medical Journal. 2012;41(1):50-2.

17. Svensson A, Ofenloch R, Bruze M, Naldi L, Cazzaniga S, Elsner P, et al. Prevalence of skin disease in a population-based sample of adults from five European countries. British Journal of Dermatology. 2018;178(5):1111-8.

18. Aman S, Nadeem M, Mahmood K, Ghafoor MB. Pattern of skin diseases among patients attending a tertiary care hospital in Lahore, Pakistan. Journal of Taibah University Medical Sciences. 2017;12(5):392-6.

19. Jain S, Barambhe M, Jain J, Jayo U, Pandey N. Prevalence of skin diseases in rural Central India: A community-based, cross-sectional, observational study. Journal of Mahatma Gandhi Institute of Medical Sciences. 2016;21(2):111.

20. Scotland NH. Scottish Burden of Disease Study, 2015 Skin and subcutaneous diseases technical overview. Edinburgh Scotland: NHS Health Scotland; 2017.

21. Furue M, Yamazaki S, Jimbow K, Tsudhida T, Amagai M, Tanaka T, et al. Prevalence of dermatological disorders in Japan: a nationwide, cross-sectional, seasonal, multicenter, hospital-based study. The Journal of dermatology. 2011;38(4):310-20.

22. Tamer E, Ilhan MN, Polat M, Lenk N, Ali N. Prevalence of skin diseases among pediatric patients in Turkey. The Journal of dermatology. 2008;35(7):413-8.

23. Bridgman AC, Fitzmaurice C, Dellavalle RP, Karimkhani Aksut C, Grada A, Naghavi M, et al. Canadian Burden of Skin Disease From 1990 to 2017: Results From the Global Burden of Disease 2017 Study. Journal of cutaneous medicine and surgery. 2020;24(2):161-73.

24. Kim GK, Del Rosso JQ, Bellew S. Skin cancer in Asians: part 1: nonmelanoma skin cancer. The Journal of clinical and aesthetic dermatology. 2009;2(8):39.

25. Gloster Jr HM, Neal K. Skin cancer in skin of color. Journal of the American Academy of Dermatology. 2006;55(5):741-60.

26. Koh D, Wang H, Lee J, Chia K, Lee H, Goh C. Basal cell carcinoma, squamous cell carcinoma and melanoma of the skin: analysis of the Singapore Cancer Registry data 1968–97. British journal of Dermatology. 2003;148(6):1161-6.

27. Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. Journal of Investigative Dermatology. 2016;136(6):1161-71.

Tables

Table 1. Numbers and prevalences of 15 skin diseases diagnosed and treated in Ubonratchathani’s healthcare services in 2018
| Skin Diseases                      | Number of cases | Prevalence (95% UI) † |
|-----------------------------------|-----------------|-----------------------|
| Total cases of skin diseases      | 110,205         | 7.33 (7.29-7.37)      |
| 1. Dermatitis                     |                 |                       |
| Atopic dermatitis                 | 969             | 0.06 (0.06-0.07)      |
| Seborrheic dermatitis             | 607             | 4.04 (3.73-4.37) x10^{-2} |
| Contact dermatitis                | 14,795          | 0.98 (0.97-1.00)      |
| 2. Viral skin diseases            | 9,466           | 0.63 (0.62-0.64)      |
| Wart                             | 496             | 0.03 (0.03-0.04)      |
| Molluscum contagiosum             | 12              | 7.98 (4.53-14.0) x10^{-4} |
| 3. Fungal skin diseases           | 13,360          | 0.89 (0.87-0.90)      |
| Tinea capitis                     | 373             | 0.02 (0.02-0.03)      |
| Other fungal skin infection       | 13,047          | 0.87 (0.85-0.88)      |
| 4. Bacterial skin diseases        | 33,294          | 2.21 (2.19-2.24)      |
| Cellulitis                        | 15,641          | 1.04 (1.02-1.06)      |
| Pyoderma                          | 13,958          | 0.93 (0.91-0.94)      |
| Impetigo                          | 5,680           | 0.38 (0.37-0.39)      |
| Abscess and other bacterial skin diseases | 14       | 9.31 (5.51-15.7) x10^{-4} |
| 5. Melanoma                       | 435             | 2.89 (2.63-3.18) x10^{-2} |
| 6. Non-melanoma skin cancers‡     | 222             | 1.48 (1.29-1.68) x10^{-2} |
| 7. Carcinoma in situ              | 21              | 1.40 (0.91-2.14) x10^{-3} |
| 8. Other skin and subcutaneous disease | 15,502     | 1.03 (1.01-1.05)      |
| 9. Pruritus                       | 5,244           | 0.35 (0.34-0.36)      |
| 10. Urticaria                     | 13,380          | 0.89 (0.87-0.90)      |
| 11. Decubitus ulcer               | 577             | 3.84 (3.54-4.16) x10^{-2} |
| 12. Acne vulgaris                 | 92              | 7.83 (7.40-8.29) x10^{-2} |
| 13. Psoriasis                     | 1,178           | 0.08 (0.07-0.08)      |
| 14. Alopecia areata               | 176             | 1.17 (1.01-1.36) x10^{-2} |
| 15. Scabies                       | 195             | 1.30 (1.13-1.49) x10^{-2} |

† Prevalence is presented in percent and 95%UI calculated using Bayesian bootstrap technique

‡ Non-melanoma skin cancers; squamous cell carcinoma and basal cell carcinoma
Table 2. YLL, YLD and DALYs of 21 skin diseases in Ubonratchathani, overall and by sex
| Skin diseases                        | Females |                     |                     |                    | Males |                     |                     |                    |
|-------------------------------------|---------|---------------------|---------------------|--------------------|-------|---------------------|---------------------|--------------------|
|                                    | YLL     | YLD                 | DALYs (95% UI)      | YLL (95% UI)       | YLD   | DALYs (95% UI)      | YLL (95% UI)       | YLD (95% UI)       | Total DALYs (95% UI) |
| Atopic dermatitis                   | NA      | 156.02              | (142.71–169.34)     | NA                 | 99.79 | (89.59–110.00)      | 90.63–108.95       | 255.82             |
| Contact dermatitis                  | NA      | 969.30              | (947.81–990.79)     | NA                 | 628.56 | (611.06–646.06)     | 612.10–645.02      | 1,597.86           |
| Seborrheic dermatitis               | NA      | 5.04                | (4.47–5.61)         | NA                 | 3.46  | (2.94–3.98)         | 3.06–3.86          | 8.50               |
| Psoriasis                           | NA      | 133.58              | (122.30–144.87)     | NA                 | 177.41 | (165.00–189.82)     | 164.38–190.44      | 310.99             |
| Cellulitis                          | 5,030.74| 473.57              | (462.48–484.67)     | 5,504.31           | 5,663.82 | (5,336.04–5,991.60) | 6,175.63          | 11,679.94          |
| Impetigo                            | NA      | 16.64               | (15.98–17.30)       | NA                 | 17.44 | (16.79–18.08)       | 16.81–18.06        | 34.08              |
| Abscess and other bacterial skin disease | NA    | 0.07                | (0.03–0.10)         | NA                 | 0.02  | (0.00–0.04)         | 0.00–0.03          | 0.08               |
| Scabies                             | NA      | 2.65                | (2.02–3.27)         | NA                 | 2.62  | (2.02–3.22)         | 2.09–3.15          | 5.27               |
| Tinea capitis                       | NA      | 0.95                | (0.80–1.10)         | NA                 | 1.28  | (1.07–1.50)         | 1.10–1.47          | 2.24               |
| Other fungal skin disease           | NA      | 47.96               | (46.95–48.97)       | NA                 | 30.32 | (29.60–31.05)       | 29.52–31.13        | 78.28              |
| Wart                                | NA      | 10.62               | (9.30–11.94)        | NA                 | 7.73  | (6.81–8.65)         | 6.67–8.79          | 18.35              |
| Molluscum contagiosum               | NA      | 0.26                | (0.05–0.47)         | NA                 | 0.19  | (0.04–0.33)         | 0.01–0.36          | 0.44               |
| Acne vulgaris                       | NA      | 7.81                | 7.81                | NA                 | 3.60  | 3.60                | 11.41              |
| Disease                        | Value (95% UI) | Value (95% UI) | Value (95% UI) | Value (95% UI) | Value (95% UI) |
|-------------------------------|----------------|----------------|----------------|----------------|----------------|
| Alopecia areata               | NA             | 4.80 (3.77–5.82) | 4.80 (3.78–5.81) | NA             | 2.07 (1.50–2.63) |
|                              |                |                |                |                | 2.07 (1.65–2.49) |
|                              |                |                |                |                | 6.86 (5.93–7.80) |
| Pruritus                      | NA             | 39.95 (38.81–41.10) | 39.95 (38.43–41.47) | NA             | 17.73 (16.82–18.64) |
|                              |                |                |                |                | 17.73 (16.82–18.64) |
|                              |                |                |                |                | 57.68 (56.45–58.92) |
| Urticaria                     | NA             | 886.14 (869.41–902.87) | 886.14 (866.41–905.87) | NA             | 558.90 (543.36–574.44) |
|                              |                |                |                |                | 558.9 (542.05–575.75) |
|                              |                |                |                |                | 1,445.04 (1,179.77–1,710.32) |
| Decubitus ulcer               | 2,141.85 (1,964.77–2,318.94) | 72.07 (63.37–80.78) | 2,213.92 (1,862.04–2,565.80) | 2,511.87 (2,272.39–2,751.35) | 80.26 (72.85–87.66) |
|                              |                |                |                |                | 2,592.13 (2,126.77–3,057.48) |
|                              |                |                |                |                | 4,806.05 (4,093.29–5,518.81) |
| Other skin and subcutaneous disease | 1,921.82 (1,719.76–2,123.88) | 53.80 (52.41–55.19) | 1,975.62 (1,543.82–2,407.42) | 2,613.48 (2,329.76–2,897.20) | 39.21 (38.22–40.20) |
|                              |                |                |                |                | 2,652.69 (2,159.04–3,146.34) |
|                              |                |                |                |                | 4,628.312 (4,004.29–5,252.34) |
| Non-melanoma skin cancers†   | 179.62 (127.89–231.35) | 27.90 (22.58–33.22) | 207.52 (85.75–329.30) | 409.89 (310.63–509.15) | 20.49 (16.79–24.20) |
|                              |                |                |                |                | 430.38 (214.67–646.10) |
|                              |                |                |                |                | 637.91 (438.49–837.32) |
| Melanoma                     | 120.42 (91.99–148.85) | 102.92 (90.89–114.95) | 223.34 (124.34–322.34) | 272.28 (219.97–324.59) | 41.50 (34.83–48.17) |
|                              |                |                |                |                | 313.78 (156.66–470.90) |
|                              |                |                |                |                | 537.12 (362.37–711.87) |
| Total                        | 9,394.45 (8,534.88–10,254.02) | 3,013.472 (2,978.44–3,048.50) | 12,407.92 (11,416.70–13,155.24) | 11,471.34 (10,155.24–12,845.59) | 2,245.416 (2,209.76–2,281.07) |
|                              |                |                |                |                | 13,716.76 (12,845.59–14,587.92) |
|                              |                |                |                |                | 26,124.68 (24,782.76–27,466.59) |

**Note†** Non-melanoma skin cancers included squamous cell carcinoma and basal cell carcinoma

95% uncertainty intervals of YLDs, YLLs and DALYs computed using a parametric bootstrap technique

YLDs = Years lost due to disability, YLLs = Years of life lost, DALYs = Disability adjusted life years, NA = Not applicable